Amanda Feilding

Amanda Feilding

Auto-generated profile, based on publicly available information

Amanda Feilding

The Beckley Foundation

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Frontiers in Human Neuroscience
Verified
Journal Article
Open access
PDF file
RCRobin L. Carhart-Harris
Robin L. Carhart-Harris
RLRobert Leech
Robert Leech
PHPeter J. Hellyer
Peter J. Hellyer
MSMurray Shanahan
Murray Shanahan
AFAmanda Feilding
Amanda Feilding
DNDavid Nutt
David Nutt
Entropy is a dimensionless quantity that is used for measuring uncertainty about the state of a system but it can also imply physical qualities, where high entropy is synonymous with high disorder. Entropy is applied here in the context of states of consciousness and their associated neural dynamics, with a particular focus on the psychedelic state. The psychedelic state is considered an exemplar of a primitive or primary state of consciousness that preceded the development of modern, adult, human, normal waking consciousness. Based on neuroimaging data with psilocybin, a classic psychedelic drug, it is argued that the defining feature of ‘primary states’ is elevated entropy in certain aspects of brain function, such as the repertoire of functional connectivity motifs that form and fragment across time. It is noted that elevated entropy in this sense, is a characteristic of systems exhibiting ‘self-organised criticality’, i.e., a property of systems that gravitate towards a ‘critical’ point in a transition zone between order and disorder in which certain phenomena such as power-law scaling appear. This implies that entropy is suppressed in normal waking consciousness, meaning that the brain operates just below criticality. It is argued that this entropy suppression furnishes consciousness with a constrained quality and associated metacognitive functions, including reality-testing and self-awareness. It is also proposed that entry into primary states depends on a collapse of the normally highly organised activity within the default-mode network (DMN) and a decoupling between the DMN and the medial temporal lobes (which are normally significantly coupled). These hypotheses can be tested by examining brain activity and associated cognition in other candidate primary states such as REM sleep and early psychosis and comparing these with non-primary states such as normal waking consciousness and the anaesthetised state.

23 January 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RCRobin L. Carhart-Harris
Robin L. Carhart-Harris
DEDavid Erritzoe
David Erritzoe
TWTim Williams
Tim Williams
JSJames M Stone
James M Stone
LRLaurence J. Reed
Laurence J. Reed
DNDavid Nutt
David Nutt
Psychedelic drugs have a long history of use in healing ceremonies, but despite renewed interest in their therapeutic potential, we continue to know very little about how they work in the brain. Here we used psilocybin, a classic psychedelic found in magic mushrooms, and a task-free functional MRI (fMRI) protocol designed to capture the transition from normal waking consciousness to the psychedelic state. Arterial spin labeling perfusion and blood-oxygen level-dependent (BOLD) fMRI were used to map cerebral blood flow and changes in venous oxygenation before and after intravenous infusions of placebo and psilocybin. Fifteen healthy volunteers were scanned with arterial spin labeling and a separate 15 with BOLD. As predicted, profound changes in consciousness were observed after psilocybin, but surprisingly, only decreases in cerebral blood flow and BOLD signal were seen, and these were maximal in hub regions, such as the thalamus and anterior and posterior cingulate cortex (ACC and PCC). Decreased activity in the ACC/medial prefrontal cortex (mPFC) was a consistent finding and the magnitude of this decrease predicted the intensity of the subjective effects. Based on these results, a seed-based pharmaco-physiological interaction/functional connectivity analysis was performed using a medial prefrontal seed. Psilocybin caused a significant decrease in the positive coupling between the mPFC and PCC. These results strongly imply that the subjective effects of psychedelic drugs are caused by decreased activity and connectivity in the brain's key connector hubs, enabling a state of unconstrained cognition.

18 September 2013 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SMSuresh D. Muthukumaraswamy
Suresh D. Muthukumaraswamy
RCRobin L. Carhart-Harris
Robin L. Carhart-Harris
RMRosalyn J. Moran
Rosalyn J. Moran
MBMatthew J. Brookes
Matthew J. Brookes
TWTim M. Williams
Tim M. Williams
DNDavid Nutt
David Nutt
Psychedelic drugs produce profound changes in consciousness, but the underlying neurobiological mechanisms for this remain unclear. Spontaneous and induced oscillatory activity was recorded in healthy human participants with magnetoencephalography after intravenous infusion of psilocybin—prodrug of the nonselective serotonin 2A receptor agonist and classic psychedelic psilocin. Psilocybin reduced spontaneous cortical oscillatory power from 1 to 50 Hz in posterior association cortices, and from 8 to 100 Hz in frontal association cortices. Large decreases in oscillatory power were seen in areas of the default-mode network. Independent component analysis was used to identify a number of resting-state networks, and activity in these was similarly decreased after psilocybin. Psilocybin had no effect on low-level visually induced and motor-induced gamma-band oscillations, suggesting that some basic elements of oscillatory brain activity are relatively preserved during the psychedelic experience. Dynamic causal modeling revealed that posterior cingulate cortex desynchronization can be explained by increased excitability of deep-layer pyramidal neurons, which are known to be rich in 5-HT2Areceptors. These findings suggest that the subjective effects of psychedelics result from a desynchronization of ongoing oscillatory rhythms in the cortex, likely triggered by 5-HT2Areceptor-mediated excitation of deep pyramidal cells.

5 October 2012 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
AEAmir Englund
Amir Englund
PMPaul D Morrison
Paul D Morrison
JNJudith Nottage
Judith Nottage
DHDominic Hague
Dominic Hague
FKFergus Kane
Fergus Kane
SKShitij Kapur
Shitij Kapur
Community-based studies suggest that cannabis products that are high in Δ9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were randomised to receive oral CBD 600mg ( n=22) or placebo ( n=26), 210 min ahead of intravenous (IV) THC (1.5 mg). Post-THC, there were lower PANSS positive scores in the CBD group, but this did not reach statistical significance. However, clinically significant positive psychotic symptoms (defined a priori as increases ≥3 points) were less likely in the CBD group compared with the placebo group, odds ratio (OR)=0.22 (χ2=4.74, p<0.05). In agreement, post-THC paranoia, as rated with the State Social Paranoia Scale (SSPS), was less in the CBD group compared with the placebo group ( t=2.28, p<0.05). Episodic memory, indexed by scores on the Hopkins Verbal Learning Task-revised (HVLT-R), was poorer, relative to baseline, in the placebo pre-treated group (-10.6±18.9%) compared with the CBD group (-0.4%±9.7 %) ( t=2.39, p<0.05). These findings support the idea that high-THC/low-CBD cannabis products are associated with increased risks for mental health.

22 May 2015 in Human Brain Mapping
Verified
Journal Article
Closed access
ALAlexander V. Lebedev
Alexander V. Lebedev
MLMartin Lövdén
Martin Lövdén
GRGidon Rosenthal
Gidon Rosenthal
AFAmanda Feilding
Amanda Feilding
DNDavid J. Nutt
David J. Nutt
RCRobin L. Carhart-Harris
Robin L. Carhart-Harris

23 September 2014 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
RCR. L. Carhart-Harris
R. L. Carhart-Harris
MKM. Kaelen
M. Kaelen
MWM. G. Whalley
M. G. Whalley
MBM. Bolstridge
M. Bolstridge
AFA. Feilding
A. Feilding
DND. J. Nutt
D. J. Nutt